Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone

Acta Neurologica Scandinavica

Volumn 123, Issue 4, 2011, Pages 252-256

  Bartosik Psujek, H ^a   Psujek, M ^a   Jaworski, J ^a   Stelmasiak, Z ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Mitoxantrone; Multiple sclerosis; S100b protein; Total tau

Indexed keywords

MITOXANTRONE; PROTEIN S100B; TAU PROTEIN;

ADULT; ARTICLE; CELL DAMAGE; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIA CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NERVE CELL LESION; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL;

ADULT; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MITOXANTRONE; MULTIPLE SCLEROSIS; NERVE GROWTH FACTORS; S100 PROTEINS; TAU PROTEINS;

EID: 79952074594     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01393.x     Document Type: Article

References (20)

1. Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological processes. Physiol Rev 2004;84:361-84.
2. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001;33:637.
3. Kapaki E, Paraskevas GP, Michalopoulu M, Kilidireas K. Increased cerebrospinal fluid tau protein in multiple sclerosis. Eur Neurol 2000;43:228-32.
4. Jiménez-Jiménez FJ, Zurdo JM, Hernanz A et al. Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis. Acta Neurol Scand 2002;106:351-4.
5. Bartosik-Psujek H, Archelos JJ. Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG. J Neurol 2004;251:414.
6. Brettschneider J, Maier M, Arda S et al. Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. Mult Scler 2005;11:261-5.
7. Terzi M, Birinci A, Cetinkaya E, Onar MK. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis. Acta Neurol Scand 2007;115:325-30.
8. Brettschneider J, Petzold A, Junker A, Tumani H. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler 2006;12:143-8.
9. Martinez-Yelamos A, Saiz A, Sanchez-Valle R et al. 14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis. Neurology 2001;57:722-4.
10. Missler U, Wandinger KP, Wiesmann M, Kaps M, Wessel K. Acute exacerbation of multiple sclerosis increases plasma levels of S-100 protein. Acta Neurol Scand 1997;96:142-4.
11. Petzold A, Eikelenboom MJ, Gveric D et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002;125:1462-73.
12. Petzold A, Brassat D, Mas P et al. Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis. Mult Scler 2004;10:281-3.
13. Lim ET, Grant D, Pashenkov M et al. Cerebrospinal fluid levels of brain specific proteins in optic neuritis. Mult Scler 2004;10:261-5.
14. Koch M, Mostert J, Heersema D, Teelken A, De Keyser J. Plasma S100beta and NSE levels and progression in multiple sclerosis. J Neurol Sci 2007;252:154-8.
15. Hein Née Maier K, Köhler A, Diem R et al. Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis. Neurosci Lett 2008;436:72-6.
16. Guimarães I, Cardoso MI, Sá MJ. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Mult Scler 2006;12:354-6.
17. Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-6.
18. Kavalci C, Pekdemir M, Durukan P et al. The value of serum tau protein for the diagnosis of intracranial injury in minor head trauma. Am J Emerg Med 2007;25:391-5.
19. Liliang PC, Liang CL, Weng HC et al. Tau proteins in serum predict outcome after severe traumatic brain injury. J Surg Res 2010; 160:302-7.
20. Wunderlich MT, Lins H, Skalej M, Wallesch CW, Goertler M. Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke. Clin Neurol Neurosurg 2006;108:558-63.